Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development
Open Access
- 10 September 2020
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-10
Abstract
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and sulindac are effective for colorectal cancer prevention in humans and some animal models, but concerns over gastro-intestinal (GI) ulceration and bleeding limit their potential for chemopreventive use in broader populations. Recently, the combination of aspirin with a phospholipid, packaged as PL-ASA, was shown to reduce GI toxicity in a small clinical trial. However, these studies were done for relatively short periods of time. Since prolonged, regular use is needed for chemopreventive benefit, it is important to know whether GI safety is maintained over longer use periods and whether cancer prevention efficacy is preserved when an NSAID is combined with a phospholipid. Methods: As a first step to answering these questions, we treated seven to eight-week-old, male and female C57B/6 Apcmin/+ mice with the NSAID sulindac, with and without phosphatidylcholine (PC) for 3-weeks. At the end of the treatment period, we evaluated polyp burden, gastric toxicity, urinary prostaglandins (as a marker of sulindac target engagement), and blood chemistries. Results: Both sulindac and sulindac-PC treatments resulted in significantly reduced polyp burden, and decreased urinary prostaglandins, but sulindac-PC treatment also resulted in the reduction of gastric lesions compared to sulindac alone. Conclusions: Together these data provide pre-clinical support for combining NSAIDs with a phospholipid, such as phosphatidylcholine to reduce GI toxicity while maintaining chemopreventive efficacy.Keywords
Funding Information
- Duncan Family Institute for Cancer Prevention and Risk Assessment
- UT MD Anderson Cancer Center Colorectal Cancer Moon Shot
- DHHS/NCI Cancer Center Support Grant (P30 CA16672-39)
- National Cancer Institute (2R42CA171408-02A1)
- National Cancer Institute (P50 CA221707)
This publication has 37 references indexed in Scilit:
- Curcumin's Effect on Intestinal Inflammation and Tumorigenesis in the Apc
Min/+
MouseJournal of Interferon & Cytokine Research, 2011
- Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal CancerJAMA, 2005
- Sulindac Inhibits β-Catenin Expression in Normal-Appearing Colon of Hereditary Nonpolyposis Colorectal Cancer and Familial Adenomatous Polyposis PatientsCancer Epidemiology, Biomarkers & Prevention, 2005
- Primary Chemoprevention of Familial Adenomatous Polyposis with SulindacNew England Journal of Medicine, 2002
- Discordant effect of aspirin and indomethacin on intestinal tumor burden inApcMin/+ miceProstaglandins, Leukotrienes and Essential Fatty Acids, 2000
- Aspirin prevents tumors in a murine model of familial adenomatous polyposisSurgery, 1998
- Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin☆☆☆Gastroenterology, 1998
- A fish oil derived concentrate enriched in eicosapentaenoic and docosahexaenoic acid as ethyl ester suppresses the formation and growth of intestinal polyps in the Min mouseCarcinogenesis, 1997
- Role of Surface-Active Phospholipids in Gastric CytoprotectionScience, 1983
- COMPARISON OF THE EFFECTS OF REGULAR AND ENTERIC-COATED ASPIRIN ON GASTRODUODENAL MUCOSA OF MANThe Lancet, 1980